高甘油三酯血症

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019 Jun 18;139(25):e1082-143.全文  摘要

Laufs U, Parhofer KG, Ginsberg HN, et al. Clinical review on triglycerides. Eur Heart J. 2020 Jan 1;41(1):99-109c.全文  摘要

Berglund L, Brunzell JD, Goldberg AC, et al; Endocrine Society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 Sep;97(9):2969-89.全文  摘要

Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Aug 31;78(9):960-93.全文  摘要

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.全文  摘要

Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017 Apr;23(Suppl 2):1-87.全文  摘要

1. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007 Apr 10;176(8):1113-20.全文  摘要

2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019 Jun 18;139(25):e1082-143.全文  摘要

3. Sandesara PB, Virani SS, Fazio S, et al. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev. 2019 Apr 1;40(2):537-57.全文  摘要

4. Sandhu S, Al-Sarraf A, Taraboanta C, et al. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis. 2011 Sep 11;10:157.全文  摘要

5. Laufs U, Parhofer KG, Ginsberg HN, et al. Clinical review on triglycerides. Eur Heart J. 2020 Jan 1;41(1):99-109c.全文  摘要

6. Hegele RA, Ginsberg HN, Chapman MJ, et al.; European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014 Aug;2(8):655-66.全文  摘要

7. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorder. N Engl J Med. 1967;276:273-281. 摘要

8. Berglund L, Brunzell JD, Goldberg AC, et al; Endocrine Society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 Sep;97(9):2969-89.全文  摘要

9. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Aug 31;78(9):960-93.全文  摘要

10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) - executive summary. JAMA. 2001 May 16;285(19):2486-97. 摘要

11. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.全文  摘要

12. Hegele RA, Borén J, Ginsberg HN, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2020 Jan;8(1):50-67. 摘要

13. Simha V. Management of hypertriglyceridemia. BMJ. 2020 Oct 12;371:m3109. 摘要

14. Brahm A, Hegele RA. Hypertriglyceridemia. Nutrients. 2013 Mar 22;5(3):981-1001.全文  摘要

15. Tóth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the national health and nutrition examination survey 2003-2006. J Clin Lipidol. 2012 Jul-Aug;6(4):325-30. 摘要

16. Toth PP, Fazio S, Wong ND, et al. Risk of cardiovascular events in patients with hypertriglyceridaemia: a review of real-world evidence. Diabetes Obes Metab. 2020 Mar;22(3):279-89.全文  摘要

17. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023 Feb 21;147(8):e93-e621.全文  摘要

18. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011 May 24;123(20):2292-333.全文  摘要

19. Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev. 2015 Feb;36(1):131-47.全文  摘要

20. Goldberg RB, Chait A. A comprehensive update on the chylomicronemia syndrome. Front Endocrinol (Lausanne). 2020 Oct 23;11:593931.全文  摘要

21. Chait A, Eckel RH. The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment. Ann Intern Med. 2019 May 7;170(9):626-34. 摘要

22. Rosenson RS, Hegele RA, Gotto AM Jr. Integrated measure for atherogenic lipoproteins in the modern era: risk assessment based on apolipoprotein B. J Am Coll Cardiol. 2016 Jan 19;67(2):202-4.全文  摘要

23. Burnett JR, Hooper AJ, Hegele RA. Remnant cholesterol and atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2020 Dec 8;76(23):2736-9.全文  摘要

24. Sniderman AD, Pencina M, Thanassoulis G. ApoB. Circ Res. 2019 May 10;124(10):1425-7.全文  摘要

25. Babirak SP, Iverius PH, Fujimoto WY, et al. Detection and characterization of the heterozygote state for lipoprotein lipase deficiency. Arteriosclerosis. 1989 May-Jun;9(3):326-34.全文  摘要

26. Stahel P, Xiao C, Hegele RA, et al. The atherogenic dyslipidemia complex and novel approaches to cardiovascular disease prevention in diabetes. Can J Cardiol. 2018 May;34(5):595-604. 摘要

27. Dron JS, Hegele RA. Genetics of hypertriglyceridemia. Front Endocrinol (Lausanne). 2020 Jul 24;11:455.全文  摘要

28. Dron JS, Wang J, Cao H, et al. Severe hypertriglyceridemia is primarily polygenic. J Clin Lipidol. 2019 Jan - Feb;13(1):80-8.全文  摘要

29. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. Arterioscler Thromb. 1992 Aug;12(8):911-9. 摘要

30. Goldberg IJ, Ibrahim N, Bredefeld C, et al. Ketogenic diets, not for everyone. J Clin Lipidol. 2021 Jan-Feb;15(1):61-7.全文  摘要

31. Abbasi F, McLaughlin T, Lamendola C, et al. High carbohydrate diets, triglyceride-rich lipoproteins, and coronary heart disease risk. Am J Cardiol. 2000 Jan 1;85(1):45-8. 摘要

32. Gjuladin-Hellon T, Davies IG, Penson P, et al. Effects of carbohydrate-restricted diets on low-density lipoprotein cholesterol levels in overweight and obese adults: a systematic review and meta-analysis. Nutr Rev. 2019 Mar 1;77(3):161-80.全文  摘要

33. Klop B, do Rego AT, Cabezas MC. Alcohol and plasma triglycerides. Curr Opin Lipidol. 2013 Aug;24(4):321-6. 摘要

34. Golden A, Kessler C. Obesity and genetics. J Am Assoc Nurse Pract. 2020 Jul;32(7):493-6. 摘要

35. Jennings J, Faselis C, Yao MD. NAFLD-NASH: an under-recognized epidemic. Curr Vasc Pharmacol. 2018;16(3):209-13. 摘要

36. Katsiki N, Mikhailidis DP, Banach M. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opin Pharmacother. 2019 Nov;20(16):2007-17. 摘要

37. Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis. 2007 Dec;7(12):787-96. 摘要

38. Waters DD, Hsue PY. Lipid abnormalities in persons living with HIV infection. Can J Cardiol. 2019 Mar;35(3):249-59. 摘要

39. Arnaldi G, Scandali VM, Trementino L, et al. Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology. 2010;92 (Suppl 1):86-90.全文  摘要

40. Salazar A, Mana J, Pinto X, et al. Low levels of high-density lipoprotein-cholesterol in patients with active sarcoidosis. Atherosclerosis. 1998 Jan;136(1):133-7. 摘要

41. Escárcega RO, García-Carrasco M, Fuentes-Alexandro S, et al. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmun Rev. 2006 Nov;6(1):48-53. 摘要

42. Aviram M, Carter A, Brook JG, et al. Chylomicronaemia in multiple myeloma. Scand J Haematol. 1985 May;34(5):436-41. 摘要

43. Markell MS, Friedman EA. Hyperlipidemia after organ transplantation. Am J Med. 1989 Nov;87(5N):61-67N. 摘要

44. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am. 1994 Jan;78(1):117-41. 摘要

45. Goldberg AS, Hegele RA. Severe hypertriglyceridemia in pregnancy. J Clin Endocrinol Metab. 2012 Aug;97(8):2589-96.全文  摘要

46. Lichtenstein AH, Appel LJ, Vadiveloo M, et al. 2021 dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2021 Dec 7;144(23):e472-e487.全文  摘要

47. United States Preventive Services Task Force. Healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: behavioral counseling interventions. Nov 2020 [internet publication].全文

48. United States Preventive Services Task Force. Healthy diet and physical activity for cardiovascular disease prevention in adults without cardiovascular disease risk factors: behavioral counseling interventions. Jul 2022 [internet publication].全文

49. Brahm AJ, Hegele RA. Chylomicronaemia: current diagnosis and future therapies. Nat Rev Endocrinol. 2015 Jun;11(6):352-62. 摘要

50. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007 Jul 18;298(3):299-308.全文  摘要

51. Huet F, Roubille C, Roubille F. Is hypertriglyceridemia atherogenic? Curr Opin Lipidol. 2019 Aug;30(4):291-9.全文  摘要

52. Hubert HB, Feinleb M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983 May;67(5):968-77.全文  摘要

53. LeBlanc S, Coulombe F, Bertrand OF, et al. Hypertriglyceridemic waist: a simple marker of high-risk atherosclerosis features associated with excess visceral adiposity/ectopic fat. J Am Heart Assoc. 2018 Apr 13;7(8):e008139.全文  摘要

54. Saeed S, Waje-Andreassen U, Nilsson PM. The association of the metabolic syndrome with target organ damage: focus on the heart, brain, and central arteries. Expert Rev Cardiovasc Ther. 2020 Sep;18(9):601-14. 摘要

55. Toth PP, Philip S, Hull M, et al. Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: a large administrative retrospective analysis. Clin Cardiol. 2019 Oct;42(10):908-13.全文  摘要

56. Kaltoft M, Langsted A, Nordestgaard BG. Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study. Eur Heart J. 2020 Jun 21;41(24):2288-99.全文  摘要

57. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017 Apr;23(Suppl 2):1-87.全文  摘要

58. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. May 2023 [internet publication].全文

59. Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2022 ACC expert consensus decision pathway on the Role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418.全文  摘要

60. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22.全文  摘要

61. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019 Sep 17;140(12):e673-91.全文  摘要

62. Chaudhry R, Viljoen A, Wierzbicki AS. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. Expert Rev Clin Pharmacol. 2018 Jun;11(6):589-98. 摘要

63. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Feb 29;3(3):CD003177.全文  摘要

64. Borén J, Packard CJ, Taskinen MR. The roles of apoc-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol (Lausanne). 2020 Jul 28;11:474.全文  摘要

65. Hegele RA, Tsimikas S. Lipid-lowering agents. Circ Res. 2019 Feb;124(3):386-404.全文  摘要

66. Gouni-Berthold I, Alexander VJ, Yang Q, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021 May;9(5):264-75. 摘要

67. Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019 Aug 8;381(6):531-42.全文  摘要

68. Nurmohamed NS, Dallinga-Thie GM, Stroes ESG. Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. Expert Rev Cardiovasc Ther. 2020 Jun;18(6):355-61.全文  摘要

69. Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022 Apr 6;43(14):1401-12.全文  摘要

70. Berberich AJ, Ziada A, Zou GY, et al. Conservative management in hypertriglyceridemia-associated pancreatitis. J Intern Med. 2019 Dec;286(6):644-50.全文  摘要

71. Mozaffarian D, Maki KC, Bays HE, et al. Effectiveness of a novel ω-3 krill oil agent in patients with severe hypertriglyceridemia: a randomized clinical trial. JAMA Netw Open. 2022 Jan 4;5(1):e2141898.全文  摘要

72. Marston NA, Giugliano RP, Im K, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019 Oct 15;140(16):1308-17.全文  摘要

73. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: preventive medication. Aug 2022 [internet publication].全文